Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 1.00 |
| ▸ | PDE1A | P54750 | 2/20 | 0.83 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.82 |
| ▸ | PDE2A | O00408 | 1/20 | 0.69 |
| ▸ | PDE8A | O60658 | 1/20 | 0.69 |
| ▸ | PDE5A | O76074 | 1/20 | 0.69 |
| ▸ | PDE9A | O76083 | 1/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.69 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.69 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927849 | 1.00 | PDE4A (1.00) | PDE4APDE1APDE1BPDE2APDE8A | |
| SCHEMBL12198193 | 0.92 | PDE4A (0.85) | PDE4APDE1APDE1BPDE2APDE8A | |
| SCHEMBL14243117 | 0.91 | PDE1A (1.00) | PDE4APDE1APDE1B | |
| SCHEMBL2472569 | 0.91 | PDE1A (0.87) | PDE4APDE1APDE1B | |
| SCHEMBL18928137 | 0.91 | PDE1A (0.87) | PDE4APDE1APDE1B | |
| SCHEMBL14243419 | 0.90 | PDE1A (1.00) | PDE4APDE1APDE1B | |
| SCHEMBL12198217 | 0.90 | PDE4A (0.82) | PDE4APDE1APDE1B | |
| SCHEMBL12198174 | 0.89 | PDE4A (0.80) | PDE4APDE1APDE1BPDE2APDE8A | |
| SCHEMBL14243423 | 0.88 | PDE4A (0.85) | PDE4APDE1APDE1B | |
| SCHEMBL29790189 | 0.88 | PDE4A (0.85) | PDE4APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367429-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2367429-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160083390-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083390-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083390-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2016-03-24 | — | — | US | disclosed |
| US-20150038474-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038474-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038474-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-02-05 | — | — | US | disclosed |
| US-20140005155-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC (US) | 2014-01-02 | — | — | US | disclosed |
| US-8536159-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536159-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536159-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110245214-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110245214-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110245214-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-10-06 | — | — | US | disclosed |
| WO-2010065149-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065149-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038474-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20160083390-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20140005155-A1 | ORGANIC COMPOUNDS | TPMT, SULT1E1, UGT2B7 | PDE4A 2122/4885PDE1A 4789/4885PDE1B 4794/4885 |
| US-20110245214-A1 | ORGANIC COMPOUNDS | CYP3A7, TPMT, UGT2B7 | PDE4A 2270/4885PDE1A 4752/4885PDE1B 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.